Emerging Chimeric Antigen Receptor (CAR) T-cell Therapy Platforms
This research identifies some of the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.
Table of Contents
1.2 Analysis Framework: The Author's Core Value
1.3 Research Methodology: Five Steps Toward Success
1.4 Key Findings of Technology Breakthrough Driving Sepsis Diagnosis
2.2 Regulatory and Ethical Perspectives on Gene Therapy
2.3 Rising Demand for Precision Medicine Strategies
2.4 Manufacturing Continues to be the Key Bottle Neck
2.5 II Generation Chimeric Antigen ReceptorS Likely to Dominate the Cell Therapy Landscape in the Future
2.6 CD-19 is the Most Common Target Antigen for Allogeneic CAR-T Therapies
3.2 University of Pennsylvania and Novartis Lead the Patent Landscape for CAR-T Cell Therapies
3.3 China and the US Lead the Patent Landscape for CAR-T Cell Therapies
3.4 Snapshot of Key Patent Grants: Novartis
3.5 Snapshot of Key Patent Grants: Cellectis and BlueBird Bio
4.2 Gene Therapy - Venture Capital Funding Assessment
4.3 Gene Therapy - Big Pharma In-licensing Deals Assessment
4.4 Strategic Insights: Cell Therapies and Gene Therapies, Viral Vector CMOS
5.2 Precision BioSciences Inc.
5.3 CRISPR Therapeutics AG
5.4 Cellectis S.A.
5.6 Bristol-Myers Squibb (BMS)
5.9 BlueBird Bio
5.10 Summary of the Scoring Methodology
5.11 Competitive Analysis of CAR-T Participants
7.2 Legal Disclaimer
A selection of companies mentioned in this report includes:
- Allogene Therapeutics
- BlueBird Bio
- Bristol-Myers Squibb (BMS)
- Cellectis S.A.
- CRISPR Therapeutics AG
- Precision BioSciences Inc.